JP6163682B2 - 記憶の一部側面を増強するためのルテイン含有組成物の使用 - Google Patents
記憶の一部側面を増強するためのルテイン含有組成物の使用 Download PDFInfo
- Publication number
- JP6163682B2 JP6163682B2 JP2012537412A JP2012537412A JP6163682B2 JP 6163682 B2 JP6163682 B2 JP 6163682B2 JP 2012537412 A JP2012537412 A JP 2012537412A JP 2012537412 A JP2012537412 A JP 2012537412A JP 6163682 B2 JP6163682 B2 JP 6163682B2
- Authority
- JP
- Japan
- Prior art keywords
- lutein
- memory
- learning
- zeaxanthin
- corner
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000015654 memory Effects 0.000 title claims description 44
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 title description 102
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 title description 81
- 235000012680 lutein Nutrition 0.000 title description 74
- 229960005375 lutein Drugs 0.000 title description 74
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 title description 74
- 239000001656 lutein Substances 0.000 title description 74
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 title description 74
- 239000000203 mixture Substances 0.000 title description 33
- 230000006886 spatial memory Effects 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000004630 mental health Effects 0.000 claims description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 4
- 229940075420 xanthine Drugs 0.000 claims 2
- 102100031007 Cytosolic non-specific dipeptidase Human genes 0.000 claims 1
- 101000919690 Homo sapiens Cytosolic non-specific dipeptidase Proteins 0.000 claims 1
- 101000606724 Penicillium janthinellum Penicillopepsin-1 Proteins 0.000 claims 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 30
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 30
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 28
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 28
- 235000010930 zeaxanthin Nutrition 0.000 description 28
- 239000001775 zeaxanthin Substances 0.000 description 28
- 229940043269 zeaxanthin Drugs 0.000 description 28
- 230000013016 learning Effects 0.000 description 27
- 230000035882 stress Effects 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 235000013305 food Nutrition 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 230000006872 improvement Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 235000015872 dietary supplement Nutrition 0.000 description 9
- 230000031836 visual learning Effects 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229930195712 glutamate Natural products 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 230000035045 associative learning Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000000324 neuroprotective effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000014214 soft drink Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 240000007643 Phytolacca americana Species 0.000 description 3
- 235000009074 Phytolacca americana Nutrition 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000035987 intoxication Effects 0.000 description 3
- 231100000566 intoxication Toxicity 0.000 description 3
- 230000008449 language Effects 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 235000005881 Calendula officinalis Nutrition 0.000 description 2
- 244000020518 Carthamus tinctorius Species 0.000 description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- 240000000785 Tagetes erecta Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- -1 carrier Substances 0.000 description 2
- 235000012182 cereal bars Nutrition 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000014106 fortified food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 230000006993 memory improvement Effects 0.000 description 2
- 235000020674 meso-zeaxanthin Nutrition 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 235000020786 mineral supplement Nutrition 0.000 description 2
- 229940029985 mineral supplement Drugs 0.000 description 2
- 150000004712 monophosphates Chemical class 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 244000187129 Bacopa monnieria Species 0.000 description 1
- 235000015418 Bacopa monnieria Nutrition 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000272470 Circus Species 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 229920001732 Lignosulfonate Polymers 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 240000005893 Pteridium aquilinum Species 0.000 description 1
- 235000009936 Pteridium aquilinum Nutrition 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000002475 cognitive enhancer Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000028252 learning or memory Effects 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 235000020772 multivitamin supplement Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000020741 pine bark extract Nutrition 0.000 description 1
- 229940106587 pine bark extract Drugs 0.000 description 1
- 235000018192 pine bark supplement Nutrition 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 235000013606 potato chips Nutrition 0.000 description 1
- 235000019684 potato crisps Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940106796 pycnogenol Drugs 0.000 description 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 239000007886 soft shell capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004006 stereotypic behavior Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000008924 yoghurt drink Nutrition 0.000 description 1
- JKQXZKUSFCKOGQ-QAYBQHTQSA-N zeaxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-QAYBQHTQSA-N 0.000 description 1
- 150000003749 zeaxanthins Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
本発明は、連合学習、連合記憶、ストレス下における学習及び記憶ならびに空間的(位置)学習など、一部のある種の記憶機能を改善するための、ルテイン及び/又はゼアキサンチンを含む新規栄養補助組成物又は食品組成物に関する。
高齢者及び若年者の両方において学習、記憶及び覚醒状態を改善するために使用することができる栄養補助組成物の開発に対する関心が高まっている。
本発明によると、単独の活性成分として又はゼアキサンチンとの組み合わせの何れかで投与されるルテインは、連合学習及び記憶、ストレス下における学習及び記憶ならびに空間的学習及び記憶など、記憶のある種の側面を強化し得ることが分かった。
連合記憶、空間記憶又はストレス下における記憶の増強を観察することと、
を含む、健常者において、連合記憶、空間記憶及びストレス下における記憶からなる群から選択される記憶の一部側面を増強する方法である。
a)ルテイン又はルテインとゼアキサンチンとの組み合わせの何れかの、ストレス関連学習及び記憶を増強する有効量と、b)適切な担体と、からなる組成物を投与することと、
ストレス下における学習及び記憶の増強を観察することと、
を含む、ストレス下における学習及び記憶を増強する方法である。
空間的学習及び記憶の増強を観察することと、
を含む、空間的学習及び記憶を増強する方法である。
ルテインとは、植物抽出物又はオレオレジンとしての、ルテインの何らかの摂取可能形態を意味する。これは、オール−E及びZ異性体の両方を含む。好ましいものは、FloraGLO(登録商標)ルテインであり、これは、およそ98%ルテイン(オール−E及びZ−異性体)及び約2%のその他のカオテノイド(caotenoids)(そのうち約0.5−1.5%がゼアキサンチン)を含有するマリーゴールド抽出物である。ルテインは、様々な油(ベニバナ、トウモロコシ)中の縣濁液として使用することができるか又はActilease(登録商標)FloraGLO(登録商標)ルテインなどのバイオアベイラビリティーが高い微小ビーズ形態に製剤化することができる。
・作業時に割り当てられた仕事の遂行を忘れないこと(いくつかの課題が未解決である場合)
・人前で話す際に事実などを覚えていること
・試験という状況下又は迅速な想起が必要とされる状況下でのより良好な成績。
・鍵、眼鏡、携帯電話又はTVリモートコントローラーなどの物品の置き忘れが少なくなる。
・家の中などの周辺環境において、運転中又は大規模な駐車場で自動車を駐車した場所を単純に思い出す際に、容易に自分の位置を確認する能力。
「栄養補助」という用語は、本明細書中で使用される場合、栄養学的及び製薬学的適用分野の両方における有用性を意味する。従って、新規栄養補助組成物は、食品/飼料及び飲料への補助物質として、及びカプセル剤もしくは錠剤などの固形製剤又は溶液もしくは縣濁液などの液体製剤であり得る腸内又は非経口適用のための製剤処方として、使用することができる。
[インビトロ神経毒性モデルにおけるルテインの効果]
グルタミン酸は、中枢神経系における主要な興奮性アミノ酸の1つであり、正常な生理機能において重要な役割を果たす。グルタミン酸機能の正常な制御機構におけるゆらぎにより、脳におけるグルタミン酸受容体の過剰な神経毒性活性化が起こり得、これは正常及び加齢脳における学習及び記憶機能に悪影響を及ぼし得る。ニューロンの初代培養を用いて、グルタミン酸中毒化によってこれらの状態を再現することができる。ニューロンの神経フィラメント細胞骨格ネットワークにおける形態学的変化により、培養ニューロンに対する影響が示された。
[新しい完全自動化の学習及び記憶のげっ歯類モデルにおけるルテイン及び/又はゼアキサンチンの効果]
ホームケージ様の環境でのマウスの自発及び学習行動の自動監視を可能にするシステムであるIntelliCage(登録商標)において、ルテイン及び/又はゼアキサンチンで処置したマウスの認知能力をビヒクル処置した週齢適合対照と比較した(New Behavior AG,Zuerich,Switzerland,www.newbehavior.com;Galsworthy et al.2005,Behav Brain Res 157:211−217;Onishchenko et al.2007,Toxicol Sci 97:428−437,Mechan et al.2009,J.Neurosci.Methods,180:43−51)。マウス頸部の首筋に埋め込まれているトランスポンダー(参照識別タグ)を読み取るIntelliCageのコーナーのセンサーにより個々のマウスが認識される。
この試験には、2つの試験群(1群あたりn=12−14):ビヒクル(対照)、ルテイン(9mg/kg BW)(FloraGLO(登録商標)ルテイン、約98%ルテイン(オール−E及びZ−異性体)及びその他のカテノイド約2%(うち約1−1.5%ゼアキサンチン)含有マリーゴールド抽出物が含まれた。
サイド識別パラダイム:連合学習及び記憶ならびに記憶及び注意の検査
連合記憶パラダイム:負の強化(ストレス)による連合学習及び記憶の検査
位置学習パラダイム:空間的学習及び記憶ならびに方向付けの検査。
このモジュールは、注意及び連合記憶を試験するために計画した。正しいコーナーを1ヶ所、各マウスに割り当てた。このコーナーにおいて、(2つのうち)片側のみを正しいものとし、緑色のLEDにより動物に示した。正しいサイドにおいて、動物はノーズポークを行い、続いて水ボトルから飲むことができた。このモジュールの間、位置の誤り(即ち正しくないコーナーに行ったパーセンテージ)及びサイドの誤り(即ち正しいコーナーの誤ったサイドでのノーズポークの%)を記録した。
このモジュールにおいて、正しいコーナーを各マウスに割り当て、光を3秒間点灯させることにより示した。従って、正しいコーナーでのノーズポークにより扉が開き、マウスはその特定のコーナー内の水に接近し、一方、各マウスが正しくないコーナーの何れかへ行った場合は、罰としてエアパフが与えられた(ストレス)。結果を図5で示すが、これは、ビヒクル処置同腹仔と比較して、ルテイン処置マウスが、水を得る(及びその結果罰を回避する)ための位置を学習し、記憶する能力が顕著に高くなったことを示す。
この学習課題において、マウスは、水に接近するために、正しいコーナーに入り、そのコーナーの何れかの側でノーズポークを行わなければならなかった。先のノーズポーク適用モジュールの間の動物の立ち寄り行動に従い、コーナーを割り当て、該当する場合、最も好まないコーナーを各マウスに対して正しいコーナーとして割り当てた。さらなるシグナル(光など)は与えず、従って、マウスがそれらの周囲及び/又はケージにおける空間手掛かりに基づき水に接近するためにコーナーの位置を記憶するよう学習しようとさせた。図6は、この試験の結果をまとめるが、これは、ルテイン処置マウスがプラセボを与えられた同腹仔よりも顕著に優れた成績を収めることを示す。
[軟ゼラチンカプセルの調製]
軟ゼラチンカプセルは、次の成分を含むように調製され得る:
[即席風味付け清涼飲料の調製]
レディ・トゥ・ドリンク(ready−to−drink)清涼飲料は、1杯(250ml)あたりおよそ12mgのルテインを含有する。強化物質として及び一般的な健康のために、1日1杯(250ml)が飲まれ得る。ストレス下における記憶の改善が見られる。
[栄養分強化ノンベイクシリアルバーの調製]
[ルテインを含有するドライタイプのドッグフード]
市販のイヌ用基礎食(例えばMera Dog”Brocken”、MERA−Tiernahrung GmbH,Marienstrasse 80−84,D−47625 Kevelaer−Wetten,Germany)に、ビタミンC(例えばROVIMIX(登録商標)C−EC、DSM Nutritional Products Ltd,Kaiseraugst,Switzerland)又はその誘導体、即ち一リン酸アスコルビルナトリウム(例えばSTAY−C(登録商標)50、DSM Nutritional Products Ltd,Kaiseraugst,Switzerland)又はL−アスコルビン酸ナトリウム/カルシウムの三リン酸、二リン酸及び一リン酸エステルの混合物(例えばROVIMIX(登録商標)STAY−C(登録商標)35、DSM Nutritional Products Ltd,Kaiseraugst,Switzerland)などの抗酸化剤とともに、ドッグフード1kgあたりおよそ5mgのルテインを与えるのに十分な量の、ルテインの溶液、ルテイン、例えば、FloraGLO(登録商標)ルテイン5%トウモロコシ油を噴霧する。より体重が重い犬の場合、適宜に混合飼料を調製する。
[ルテインを含有するウェットタイプのキャットフード]
市販のネコ用基礎食(例えばHappy Cat“Adult”、Tierfeinnahrung,Suedliche Hauptstrasse 38,D−86517 Wehringen,Germany)を、水中で、ビタミンC(例えばROVIMIX(登録商標)C−EC、DSM Nutritional Products Ltd,Kaiseraugst,Switzerland)又はその誘導体、即ち一リン酸アスコルビルナトリウム(例えばSTAY−C(登録商標)50、DSM Nutritional Products Ltd,Kaiseraugst,Switzerland)又はL−アスコルビン酸ナトリウム/カルシウムの三リン酸、二リン酸及び一リン酸エステルの混合物(例えばROVIMIX(登録商標)STAY−C(登録商標)35、DSM Nutritional Products Ltd,Kaiseraugst,Switzerland)などの抗酸化剤とともに、キャットフード1kgあたり3mgの1日用量のルテインをネコに与えるのに十分な量のルテインの溶液、例えば、FloraGLO(登録商標)ルテイン5%トウモロコシ油と混合する。約90重量%の乾燥物を含有するように食品組成物を乾燥させる。
Claims (2)
- 自身の精神的健康を害する何れの状態でもない対象において、連合記憶、空間記憶及びストレス下における記憶からなる群から選択される記憶の一部側面を増強するための医薬組成物を製造するための、ルテインとゼアキサンチンとの組み合わせの有効量及び適切な担体の使用。
- 前記ルテインとゼアキサンチンとの組み合わせが、前記記憶の一部側面を増強する活性化合物である、請求項1の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27282309P | 2009-11-09 | 2009-11-09 | |
US61/272,823 | 2009-11-09 | ||
PCT/EP2010/066949 WO2011054944A1 (en) | 2009-11-09 | 2010-11-05 | Use of lutein containing compositions to improve certain aspects of memory |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013510129A JP2013510129A (ja) | 2013-03-21 |
JP6163682B2 true JP6163682B2 (ja) | 2017-07-19 |
Family
ID=43304680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012537412A Active JP6163682B2 (ja) | 2009-11-09 | 2010-11-05 | 記憶の一部側面を増強するためのルテイン含有組成物の使用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20120232162A1 (ja) |
EP (1) | EP2498765A1 (ja) |
JP (1) | JP6163682B2 (ja) |
KR (1) | KR101766932B1 (ja) |
CN (2) | CN102612364A (ja) |
BR (1) | BR112012010964A2 (ja) |
MX (1) | MX353505B (ja) |
WO (1) | WO2011054944A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201508975SA (en) * | 2013-05-24 | 2015-12-30 | Meiji Co Ltd | Motility function-improving agent |
EP3265069A4 (en) | 2015-03-02 | 2018-11-07 | OmniActive Health Technologies Limited | Method for stress management and overall health status improvement and compositions used therein |
JP7130635B2 (ja) * | 2017-06-01 | 2022-09-05 | 参天製薬株式会社 | ルテイン類またはその塩およびヒシ属植物の加工物を含有する脳機能障害の予防および/または改善用組成物 |
NL2019436B1 (en) | 2017-08-23 | 2019-03-07 | Newtricious Bv | Composition comprising a xantophyll and an omega-3 fatty acid and method of use thereof |
CA3112902A1 (en) | 2018-09-28 | 2020-04-02 | Otsuka Pharmaceutical Factory, Inc. | Mammal cell preserving solution containing acarbose or stachyose |
CN111838321A (zh) * | 2020-08-18 | 2020-10-30 | 青岛大学 | 一种含叶黄素和益生元的老年营养包及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07224029A (ja) * | 1994-02-09 | 1995-08-22 | Sogo Biyou Ikagaku Kenkyusho:Kk | 抗酸化活性をもつカロチノイド含有エキス、その製造法及び抗酸化剤 |
US6572899B1 (en) * | 2002-07-03 | 2003-06-03 | Vitacost.Com, Inc. | Memory loss treatment formulation |
US20060205826A1 (en) * | 2005-03-09 | 2006-09-14 | Romero Francisco J | Method of using carotenoids in the prevention of cognitive decline and for other neuroprotection functions |
WO2006116755A2 (en) | 2005-04-28 | 2006-11-02 | Trustees Of Tufts College | Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function |
EP2123263A1 (en) * | 2007-02-14 | 2009-11-25 | Tohoku University | Composition and method for suppressing lipid peroxidation in erythrocytes |
-
2010
- 2010-11-05 WO PCT/EP2010/066949 patent/WO2011054944A1/en active Application Filing
- 2010-11-05 US US13/505,854 patent/US20120232162A1/en not_active Abandoned
- 2010-11-05 CN CN2010800508339A patent/CN102612364A/zh active Pending
- 2010-11-05 KR KR1020127014671A patent/KR101766932B1/ko active Active
- 2010-11-05 CN CN201611127318.1A patent/CN107050000A/zh active Pending
- 2010-11-05 MX MX2012005441A patent/MX353505B/es active IP Right Grant
- 2010-11-05 EP EP10773633A patent/EP2498765A1/en not_active Withdrawn
- 2010-11-05 BR BR112012010964A patent/BR112012010964A2/pt not_active Application Discontinuation
- 2010-11-05 JP JP2012537412A patent/JP6163682B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CN107050000A (zh) | 2017-08-18 |
WO2011054944A1 (en) | 2011-05-12 |
BR112012010964A2 (pt) | 2018-09-11 |
KR20120115253A (ko) | 2012-10-17 |
JP2013510129A (ja) | 2013-03-21 |
KR101766932B1 (ko) | 2017-08-09 |
MX353505B (es) | 2018-01-17 |
MX2012005441A (es) | 2012-07-03 |
EP2498765A1 (en) | 2012-09-19 |
CN102612364A (zh) | 2012-07-25 |
US20120232162A1 (en) | 2012-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5584937B2 (ja) | ステビア抽出物またはステビア抽出物構成物質を含有する新規な栄養補給食品組成物およびその使用 | |
RU2507742C2 (ru) | Композиции и способы усиления когнитивной функции | |
KR101564106B1 (ko) | 우울증 치료를 위한 트라이사이클릭 디테르펜 및 이의 유도체를 포함하는 식이 또는 약학 조성물 | |
JP6163682B2 (ja) | 記憶の一部側面を増強するためのルテイン含有組成物の使用 | |
US9326956B2 (en) | Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate | |
JP2021506867A (ja) | 認知的及び精神的健康のためのプロバイオティクス | |
CN101277739B (zh) | 用于增强认知功能的方法和组合物 | |
JP2011167203A (ja) | アスタキサンチンを含有する経口投与組成物、その製造方法、及びその使用方法 | |
US20110045109A1 (en) | Novel nutraceutical compositions containing whole-fruit zanthoxylum bungeanum extract for cognition | |
CN107427485B (zh) | 用于治疗焦虑症的中链脂肪酸及其甘油三酯 | |
JP2004357506A (ja) | ペット用サプリメント | |
JP5849368B2 (ja) | 認知力のためのチモールおよび/またはp−シメンまたは植物抽出物を含有する新規な栄養補給食品組成物 | |
JP2010510270A (ja) | 三環式ジテルペンおよびその誘導体の混合物を含有するセージ抽出物を含む食品および医薬品組成物ならびにこれらの使用 | |
JP2011063552A (ja) | 身体活動促進剤 | |
MX2011001169A (es) | Metodos y composiciones para prevenir, reducir o tratar el daño causado por la isquemia y condiciones tipo isquemia. | |
JP6071988B2 (ja) | 身体活動促進剤 | |
WO2019116329A1 (en) | Use of maltodextrin for enhancing or improving cognition and/or stimulating brain development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140916 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141216 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150914 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150924 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20151120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170404 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170531 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6163682 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |